Plasma insulin-like growth Factor-Binding protein 7 predicts 20-Year Cancer-Specific and overall survival in ARIC
Clicks: 9
ID: 321227
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
2.4
/100
9 views
8 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #254 of 357 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 357 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Insulin-like growth factor-binding protein 7 (IGFBP7) may influence physiology by modulating IGF signaling and/or by IGF-independent mechanisms. Prior studies suggest positive associations of circulating IGFBP7 with cancer incidence and all-cause mortality. We analyzed whether IGFBP7 is associated with cancer incidence, cancer mortality, and all-cause mortality. METHODS: We conducted a prospective cohort analysis of 10,834 participants with no cancer history for cancer analyses, and 11,761 participants for all-cause mortality analyses in the Atherosclerosis Risk in Communities study. Participants aged 46-70 years were followed for >2 decades. Plasma IGFBP7 was measured by SomaScan® 5K assay (relative fluorescence units). Incident cancers were ascertained primarily by state cancer registry linkage and mortality confirmed by death certificates. We estimated the association between quartiles of log2-transformed IGFBP7 and outcomes using Cox proportional hazards regression adjusting for age, sex, race/center, and major risk factors, and predicted 20-year survival across IGFBP7 quartiles. RESULTS: IGFBP7 was positively associated with cancer mortality (1,420 cancer deaths; Q4 vs. Q1: HR = 1.27, 95% CI 1.08-1.50), especially lung (HR = 1.48, 95% CI 1.07-2.05), but not with cancer incidence (3,347 cases; HR = 1.01, 95% CI 0.91-1.12). IGFBP7 was positively associated with all-cause mortality (6,981 deaths; HR = 1.33, 95% CI 1.23-1.43). The highest IGFBP7 quartile had lowest 20-year predicted cancer-specific survival (unadjusted model only) and survival overall. IGFBP7 was not strongly correlated with IGF-1. CONCLUSIONS: High circulating IGFBP7 may be a risk factor for cancer mortality, especially lung, and all-cause mortality. Our observations justify confirmatory studies and efforts to understand underlying mechanisms.
| Reference Key |
openalex_W7168579436
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Vernon A Burk, Michael N Pollak, Corinne E. Joshu, Anna Prizment, Elizabeth A Platz |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 2026 |
| DOI |
10.1093/jnci/djag238
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.